Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

Dr. Joshua Hare to Chair the Board

LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of heart failure.

The Medical Advisory Board will play an important supportive role in the design and oversight of the planned CDP-1050 Phase 2 clinical trial and assist in addressing regulatory and patients' welfare issues. It is composed of internationally recognized leaders in the field of heart failure; all of whom have extensive experience in the design and execution of clinical trials aimed at improved care of patients with heart failure.

CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.

The Medical Advisory Board is chaired by Joshua M. Hare, M.D., the Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology, and Director of the Interdisciplinary Stem Cell Institute at University of Miami, Miller School of Medicine. He has pioneered the use of stem cell therapy to repair damaged hearts. Dr. Hare has authored and co-authored numerous peer-reviewed publications including a report on a multi-center clinical trial with oxypurinol, a modifier of cellular redox potential, in patients with symptomatic heart failure. He served as the principal investigator of that clinical trial. Dr. Hare has also authored a New England Journal of Medicine editorial on redox-nitric oxide balance in the cardiovascular system.

Other members of the Medical Advisory Board include:

Wilson S. Colucci, M.D., is the Thomas J. Ryan Professor of
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Texas (PRWEB) August 21, 2014 ... Seaweed Fertilizer Industry” is a professional and ... market. The report provides basic Seaweed Fertilizer ... and industry chain structure as well as ... market analysis, including domestic market as well ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... LOS ANGELES, May 3, 2012 MD+DI ... UBM Canon,s leading brand providing the medical device industry with ... a 2012 Maggie Award for Best Overall Category in the ... 2011 issue. MD+DI,s May 2011 cover ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) ... percent over the same period of 2011. Total revenues for ... $83.3 million for the same period of 2011. Total revenue ...
... May 3, 2012 Immunomic Therapeutics, Inc., ("ITI," Lancaster, ... MD, announced that the U.S. Food and Drug Administration ... Drug Application ("IND") filed for the allergy immunotherapy, JRC- ... ITI that there will be no clinical hold and ...
Cached Biology Technology:MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade 2PDL BioPharma Announces First Quarter 2012 Financial Results 2PDL BioPharma Announces First Quarter 2012 Financial Results 3PDL BioPharma Announces First Quarter 2012 Financial Results 4PDL BioPharma Announces First Quarter 2012 Financial Results 5Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy 2Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy 3
(Date:8/22/2014)... is available in German . ... in PCFs proteins are fixated in a way so ... Next, the HZB and Fudan University researchers are planning ... functional materials. Their findings are being published today in ... , Proteins are sensitive molecules. Everyone knows that ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... -- A new study of American singles found ... have the highest orgasm rates. On average, men ... their sexual orientation making little difference. For women, ... women experience orgasm 62.9 percent of the time ... this pattern varies with women,s sexual orientation, with ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... - (Toronto) A new study from the Centre for ... a variation of a specific gene may play a role ... of Alzheimer,s cases. This innovative study has combined genetics and ... developing late-onset Alzheimer,s disease long before symptoms appear. The ...
... examine the response to noise of a diverse range of ... found that many families of crustaceans previously assumed to be ... Lizard Island on the Great Barrier Reef, the team collected ... webs. On each of 34 nights, one light trap ...
... (Minority Access to Research Careers) Program has announced the ... Sports Medicine (ACSM) Southeast Chapter Annual Meeting in Greenville, ... to promote the entry of underrepresented minority students, postdoctorates ... community and to encourage the participation of young scientists ...
Cached Biology News:Combining brain imaging, genetic analysis may help identify people at early risk of Alzheimer's 2Rowdy residents warn crustaceans away from perilous reefs 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: